ABC-07 : chemotherapy with or without SBRT in cholangiocarcinoma

Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the randomized ABC-07 trial (ISRCTN10639376) of gemcitabine plus cisplatin alone versus gemcitabine plus cisplatin followed by stereotactic body radiation therapy (SBRT) in liver-limited cholangiocarcinoma. Analysis of progression-free survival (PFS) and overall survival (OS) revealed that the PFS was slightly worse in the SBRT arm, while OS was essentially the same in both treatment groups, as indicated by the collected hazard ratios. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.